Goldman Sachs has upgraded Qiagen NV (NYSE:QGEN) from Neutral to Buy, citing its steady income from selling sample preparation tools and diagnostics, defensive growth potential, and favorable valuation compared to the sector. Qiagen's business is considered resilient, even in times of reduced spending on big equipment, and is trading at a significant discount to the sector despite high single-digit to low double-digit core organic growth over the past year. The company's end market exposure and defensive nature are seen as advantages in the current uncertain environment, particularly in Pharma R&D and Capex spending. QGEN shares saw a 0.95% increase to $41.84.